Skip to main content
Top
Published in: Current Osteoporosis Reports 1/2012

01-03-2012 | Current Therapeutics (SL Silverman, Section Editor)

Secondary Fracture Prevention

Author: Robert A. Adler

Published in: Current Osteoporosis Reports | Issue 1/2012

Login to get access

Abstract

Osteoporosis causes no symptoms until there is a fracture. Although screening for osteoporosis is recommended for some populations, patients may present with a fragility fracture. Such patients are at high risk for subsequent fractures. Despite this high risk and the presence of generally safe and effective osteoporosis therapy, only a minority of low trauma fracture patients have evaluation and treatment of underlying osteoporosis. A brief summary of the evaluation and medical treatment of the post-fracture patient is provided. Several institutions, integrated health systems, and countries have instituted programs to identify, evaluate, and treat fragility fracture patients. Such programs have had variable success. This article describes some of the programs that work, their cost-effectiveness, and the applicability to the generally non-integrated US health care system. It is clear that better management of the post-fracture patient (and other high-risk patients) will lead to fewer fractures, decreased morbidity and mortality, and long-term cost savings.
Literature
1.
go back to reference Lim LS, Hoeksema LJ, Sherin KM. ACPM Prevention Practice Committee, Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice. Am J Prev Med. 2009;36:366–75.PubMedCrossRef Lim LS, Hoeksema LJ, Sherin KM. ACPM Prevention Practice Committee, Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice. Am J Prev Med. 2009;36:366–75.PubMedCrossRef
2.
go back to reference National Osteoporosis Foundation, Clinician’s guide to prevention and treatment of osteoporosis. Washington, DC 2008. National Osteoporosis Foundation, Clinician’s guide to prevention and treatment of osteoporosis. Washington, DC 2008.
3.
go back to reference Preventive Services US. Task Force, Screening for osteoporosis: U.S. preventive services task force recommendation statement. Ann Intern Med. 2011;154:356–64. Preventive Services US. Task Force, Screening for osteoporosis: U.S. preventive services task force recommendation statement. Ann Intern Med. 2011;154:356–64.
4.
go back to reference Kanis JA, Johansson H, Oden A, et al. The effects of a FRAX revision for the USA. Osteoporos Int. 2010;21:35–40.PubMedCrossRef Kanis JA, Johansson H, Oden A, et al. The effects of a FRAX revision for the USA. Osteoporos Int. 2010;21:35–40.PubMedCrossRef
5.
go back to reference Nguyen ND, Frost SA, Center JR, et al. Development of a nomogram for individualizing hip fracture risk in men and women. Osteoporos Int. 2008;18:1109–17.CrossRef Nguyen ND, Frost SA, Center JR, et al. Development of a nomogram for individualizing hip fracture risk in men and women. Osteoporos Int. 2008;18:1109–17.CrossRef
6.
go back to reference Compston J, Cooper A, Cooper C, et al. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas. 2009;62:105–8.PubMedCrossRef Compston J, Cooper A, Cooper C, et al. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas. 2009;62:105–8.PubMedCrossRef
7.
go back to reference Andrade SF, Majumdar SR, Chan A, et al. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med. 2003;163:2052–7.PubMedCrossRef Andrade SF, Majumdar SR, Chan A, et al. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med. 2003;163:2052–7.PubMedCrossRef
8.
go back to reference Kamel HK, Hussain MS, Tariq ST, et al. Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture. Am J Med. 2000;109:326–8.PubMedCrossRef Kamel HK, Hussain MS, Tariq ST, et al. Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture. Am J Med. 2000;109:326–8.PubMedCrossRef
9.
go back to reference Elliot-Gibson V, Bogoch ER, Jamal SA, et al. Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int. 2004;15:767–78.PubMedCrossRef Elliot-Gibson V, Bogoch ER, Jamal SA, et al. Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int. 2004;15:767–78.PubMedCrossRef
10.
go back to reference Torgerson DJ, Dolan P. Prescribing by general practitioners after an osteoporotic fracture. Ann Rheum Dis. 1998;57:378–9.PubMedCrossRef Torgerson DJ, Dolan P. Prescribing by general practitioners after an osteoporotic fracture. Ann Rheum Dis. 1998;57:378–9.PubMedCrossRef
11.
go back to reference Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid in reducing clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799–809.PubMedCrossRef Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid in reducing clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799–809.PubMedCrossRef
12.
go back to reference Van Staa TP, Leufkens HG, Cooper C. Does a fracture at one site predict later fractures at other sites? A British cohort study. Osteoporos Int. 2002;13:624–9.PubMedCrossRef Van Staa TP, Leufkens HG, Cooper C. Does a fracture at one site predict later fractures at other sites? A British cohort study. Osteoporos Int. 2002;13:624–9.PubMedCrossRef
13.
go back to reference Bone HG, Hosking D, Devogelaer JP, et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189–99.PubMedCrossRef Bone HG, Hosking D, Devogelaer JP, et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189–99.PubMedCrossRef
14.
go back to reference Watts NB, Josse RG, Hamdy RC, et al. Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab. 2003;88:542–9.PubMedCrossRef Watts NB, Josse RG, Hamdy RC, et al. Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab. 2003;88:542–9.PubMedCrossRef
15.
go back to reference Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of osteoporosis. N Engl J Med. 2007;356:1809–22.PubMedCrossRef Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of osteoporosis. N Engl J Med. 2007;356:1809–22.PubMedCrossRef
16.
go back to reference Leslie WD, Lix LM. Manitoba bone density program, simplified 10-year absolute fracture risk assessment: a comparison of men and women. J Clin Densitom. 2010;13:141–6.PubMedCrossRef Leslie WD, Lix LM. Manitoba bone density program, simplified 10-year absolute fracture risk assessment: a comparison of men and women. J Clin Densitom. 2010;13:141–6.PubMedCrossRef
17.
go back to reference Fitzpatrick LA. Secondary causes of osteoporosis. Mayo Clin Proc. 2002;77:453–68.PubMed Fitzpatrick LA. Secondary causes of osteoporosis. Mayo Clin Proc. 2002;77:453–68.PubMed
18.
go back to reference Tannenbaum C, Clark J, Schwartzman K, et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab. 2002;87:4431–7.PubMedCrossRef Tannenbaum C, Clark J, Schwartzman K, et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab. 2002;87:4431–7.PubMedCrossRef
19.
go back to reference Ryan CS, Petkov VI, Adler RA. Osteoporosis in men: the value of laboratory testing. Osteoporos Int. 2011;22:1845–53.PubMedCrossRef Ryan CS, Petkov VI, Adler RA. Osteoporosis in men: the value of laboratory testing. Osteoporos Int. 2011;22:1845–53.PubMedCrossRef
20.
go back to reference • Ross AC, Manson JE, Abrams SA, et al. The 2011 report of dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol. 2011;96:53–8. This is the short version of the IOM report on calcium and vitamin D intake. It is based on a thorough review of the literature on the effects of dietary/supplemental calcium and vitamin D on bone health. CrossRef • Ross AC, Manson JE, Abrams SA, et al. The 2011 report of dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol. 2011;96:53–8. This is the short version of the IOM report on calcium and vitamin D intake. It is based on a thorough review of the literature on the effects of dietary/supplemental calcium and vitamin D on bone health. CrossRef
21.
go back to reference • Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911–30. This review of vitamin D provides recommendations for vitamin D that are somewhat different from those of the IOM. For the patient with osteoporosis and/or fracture, the authors provide a rationale for a higher vitamin D target. PubMedCrossRef • Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911–30. This review of vitamin D provides recommendations for vitamin D that are somewhat different from those of the IOM. For the patient with osteoporosis and/or fracture, the authors provide a rationale for a higher vitamin D target. PubMedCrossRef
22.
go back to reference Saag KG, Zanchetta JR, Devogealer J-P, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60:3346–55.PubMedCrossRef Saag KG, Zanchetta JR, Devogealer J-P, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60:3346–55.PubMedCrossRef
23.
go back to reference Adler RA, Gill RS. Clinical utility of denosumab for treatment of bone loss in men and women. Clin Interven Aging. 2011;6:1–6. Adler RA, Gill RS. Clinical utility of denosumab for treatment of bone loss in men and women. Clin Interven Aging. 2011;6:1–6.
24.
go back to reference • Jennings LA, Auerbach AD, Maselli J, et al. Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture. J Am Geriatr Soc. 2010;58:650–7. This review demonstrates just how few hospitalized fracture patients receive treatment for underlying osteoporosis. PubMedCrossRef • Jennings LA, Auerbach AD, Maselli J, et al. Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture. J Am Geriatr Soc. 2010;58:650–7. This review demonstrates just how few hospitalized fracture patients receive treatment for underlying osteoporosis. PubMedCrossRef
25.
go back to reference •• Majumdar SR. A T-2 translational research perspective on interventions to improve post-fracture osteoporosis care. Osteoporos Int. 2011;22 Suppl 3:S471–6. This recent review provides information on programs to improve post-fracture management in Canada. CrossRef •• Majumdar SR. A T-2 translational research perspective on interventions to improve post-fracture osteoporosis care. Osteoporos Int. 2011;22 Suppl 3:S471–6. This recent review provides information on programs to improve post-fracture management in Canada. CrossRef
26.
go back to reference Streeten EA, Mohamed A, Gandhi A, et al. The inpatient consultation approach to osteoporosis treatment in patients with a fracture. Is automatic consultation needed? J Bone Joint Surg Am. 2006;88:1968–74.PubMedCrossRef Streeten EA, Mohamed A, Gandhi A, et al. The inpatient consultation approach to osteoporosis treatment in patients with a fracture. Is automatic consultation needed? J Bone Joint Surg Am. 2006;88:1968–74.PubMedCrossRef
27.
go back to reference Glowacki J, Harris MB, Simon J, et al, Brigham fracture intervention team initiatives for hospital patients with hip fractures: a paradigm shift. Int J Endocrinol 2010, 590751. Glowacki J, Harris MB, Simon J, et al, Brigham fracture intervention team initiatives for hospital patients with hip fractures: a paradigm shift. Int J Endocrinol 2010, 590751.
28.
go back to reference •• Newman ED. Perspectives on pre-fracture intervention strategies: the Geisinger Health System osteoporosis program. Osteoporos Int. 2011;22(Suppl3):S451–5. The Geisinger Clinic has instituted a screening program to prevent fractures and to evaluate and treat those who have already fractured. They show the positive consequences of such a program. CrossRef •• Newman ED. Perspectives on pre-fracture intervention strategies: the Geisinger Health System osteoporosis program. Osteoporos Int. 2011;22(Suppl3):S451–5. The Geisinger Clinic has instituted a screening program to prevent fractures and to evaluate and treat those who have already fractured. They show the positive consequences of such a program. CrossRef
29.
go back to reference •• Dell R. Fracture prevention in Kaiser Permanente Southern California. Osteoporos Int. 2011;22 Suppl 3:S457–60. Southern California Kaiser Permanente has been in the forefront in providing programs to identify patients at risk for fracture or having had an osteoporotic fracture. This review demonstrates the many benefits of such a program. CrossRef •• Dell R. Fracture prevention in Kaiser Permanente Southern California. Osteoporos Int. 2011;22 Suppl 3:S457–60. Southern California Kaiser Permanente has been in the forefront in providing programs to identify patients at risk for fracture or having had an osteoporotic fracture. This review demonstrates the many benefits of such a program. CrossRef
30.
go back to reference Rosen CJ, Khosla S. Placebo-controlled trials in osteoporosis – proceeding with caution. N Engl J Med. 2010;363:1365–7.PubMedCrossRef Rosen CJ, Khosla S. Placebo-controlled trials in osteoporosis – proceeding with caution. N Engl J Med. 2010;363:1365–7.PubMedCrossRef
31.
go back to reference Majumdar SR, Johnson JA, Bellerose D, et al. Nurse case manager vs. multifaceted intervention to improve quality of osteoporosis care after wrist fracture: randomized controlled pilot study. Osteoporos Int. 2011;22:223–30.PubMedCrossRef Majumdar SR, Johnson JA, Bellerose D, et al. Nurse case manager vs. multifaceted intervention to improve quality of osteoporosis care after wrist fracture: randomized controlled pilot study. Osteoporos Int. 2011;22:223–30.PubMedCrossRef
32.
go back to reference •• McLellan AR, Wolowacz SE, Zimovetz EA, et al. Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporos Int. 2011;22:2083–98. The FLS instituted in many UK hospitals has been proven to be a cost-effective method to decrease further fractures, prevent suffering, and save money. PubMedCrossRef •• McLellan AR, Wolowacz SE, Zimovetz EA, et al. Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporos Int. 2011;22:2083–98. The FLS instituted in many UK hospitals has been proven to be a cost-effective method to decrease further fractures, prevent suffering, and save money. PubMedCrossRef
33.
go back to reference Kannegaard PN, van der Mark S, Eiken P, Abrahamsen B. Excess mortality in men compared with women following a hip fracture: national analysis of co-medications, co-morbidity, and survival. Age Ageing. 2010;39:203–9.PubMedCrossRef Kannegaard PN, van der Mark S, Eiken P, Abrahamsen B. Excess mortality in men compared with women following a hip fracture: national analysis of co-medications, co-morbidity, and survival. Age Ageing. 2010;39:203–9.PubMedCrossRef
34.
go back to reference Beaupre LA, Morrish DW, Hanley DA, et al. Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos Int. 2011;22:983–91.PubMedCrossRef Beaupre LA, Morrish DW, Hanley DA, et al. Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos Int. 2011;22:983–91.PubMedCrossRef
35.
go back to reference •• Center JR, Bliuc D, Nguyen ND, et al. Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab. 2011;96:1006–14. Amid all the many reports of side effects of bisphosphonates, this review demonstrates that overall mortality is lower in people taking bisphosphonates. PubMedCrossRef •• Center JR, Bliuc D, Nguyen ND, et al. Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab. 2011;96:1006–14. Amid all the many reports of side effects of bisphosphonates, this review demonstrates that overall mortality is lower in people taking bisphosphonates. PubMedCrossRef
36.
go back to reference Sambrook PN, Cameron ID, Chen JS, et al. Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study. Osteoporos Int. 2011;22:2551–6.PubMedCrossRef Sambrook PN, Cameron ID, Chen JS, et al. Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study. Osteoporos Int. 2011;22:2551–6.PubMedCrossRef
37.
go back to reference Bunta AD. It is time for everyone to own the bone. Osteoporos Int. 2011;22 Suppl 3:S477–82.CrossRef Bunta AD. It is time for everyone to own the bone. Osteoporos Int. 2011;22 Suppl 3:S477–82.CrossRef
38.
go back to reference Adler RA, Semla T, Cunningham F, Pogach L, The VHA male osteoporosis program – a national model for bone health, submitted for publication. Adler RA, Semla T, Cunningham F, Pogach L, The VHA male osteoporosis program – a national model for bone health, submitted for publication.
Metadata
Title
Secondary Fracture Prevention
Author
Robert A. Adler
Publication date
01-03-2012
Publisher
Current Science Inc.
Published in
Current Osteoporosis Reports / Issue 1/2012
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-011-0090-z

Other articles of this Issue 1/2012

Current Osteoporosis Reports 1/2012 Go to the issue

Current Therapeutics (SL Silverman, Section Editor)

Osteoporosis After Transplantation

Future Therapeutics (P Miller, Section Editor)

Nitric Oxide Donors for the Treatment of Osteoporosis

Future Therapeutics (P Miller, Section Editor)

Oral Calcitonin

Current Therapeutics (SL Silverman, Section Editor)

Assessment of Fracture Risk

Future Therapeutics (P Miller, Section Editor)

Sclerostin: Therapeutic Horizons Based Upon Its Actions